Monoclonal antibody · Inhibitor of Coagulation factor XI (F11) · developed by REGENERON PHARMACEUTICALS
Amrecibart is an antibody that binds the apple 2 (A2) domain of coagulation factor XI and its activated form, FXIa. By preventing intrinsic pathway-triggered FXI activation, it inhibits contact activation-initiated blood coagulation and thrombus formation. It is being studied in peripheral artery disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07318610 | Phase 3 | Peripheral Artery Disease (PAD) | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Peripheral Artery Disease (PAD)
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →